Skip to main content

Liraglutide vs DSIP

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

DSIP

Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.

Full details →

Side-by-Side Comparison

AspectLiraglutideDSIP
MechanismBinds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties.
Typical DosageSaxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically.
AdministrationSubcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use.
Side EffectsNausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.May cause grogginess upon waking, vivid dreams, or temporary headaches.
Best For

Key Differences

Unique to Liraglutide:

Unique to DSIP:

Detailed Analysis

DSIP and Liraglutide are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose DSIP for Recovery & Healing, Sleep Quality. Choose Liraglutide for Fat Loss.

Ready to Learn More?